<DOC>
	<DOCNO>NCT01996696</DOCNO>
	<brief_summary>In current clinical practice , acceptable standard treatment locally advanced prostate cancer radiation therapy combination hormone therapy ( call Treatment B Group B study ) . However , despite best treatment , risk prostate cancer may eventually return . As well , hormonal therapy give treat prostate cancer know cause harmful effect , patient use hormone gain weight , develop diabetes , increase cholesterol level , increase blood pressure , and/or heart problem . This study look whether Metformin , drug commonly use treat diabetes , prevent patient develop harmful effect hormonal therapy . In treat diabetes , Metformin know decrease patient ' sugar level also prevent patient gain weight , decrease cholesterol level , decrease number heart problem allow patient live longer . As result , researcher study hopeful Metformin also beneficial men prostate cancer hormonal therapy prevent develop problem .</brief_summary>
	<brief_title>Prevention Metabolic Syndrome Increased Weight Using Metformin Concurrent Androgen Deprivation Therapy Radiotherapy Locally Advanced Adenocarcinoma Prostate</brief_title>
	<detailed_description>This study examine role Metformin mean prevent increase weight well prevalence severity metabolic syndrome , associate morbidity , amongst men locally advance , biopsy confirm adenocarcinoma prostate ( PCa ) plan receive curative intent therapy androgen deprivation therapy ( ADT ) external beam radiotherapy ( EBRT ) prostate . Males age biopsy confirm high tier intermediate risk PCa ( Gleason score 7 PSA 10-20 ) high risk PCa ( T3 ; and/or Gleason Score ≥ 8.0 ; and/or PSA ≥ 20 ng/mL ) ECOG 0 1 , non-diabetic evidence metastatic PCa randomize either : Group A : Metformin 500mg PO TID x 30-36 month total , neoadjuvant adjuvant ADT x18-36 month EBRT 46 Gy/23 # pelvic lymph node ( optional ) ; plus prostate boost 78 Gy/39 # brachytherapy boost ( 110-115 Gy ) OR Group B : Identical placebo TID x 20-36 month total , neoadjuvant adjuvant ADT x18-36 month EBRT 46 Gy/23 # pelvic lymph node ( optional ) ; plus prostate boost 78 Gy/39 # brachytherapy boost ( 110-115 Gy ) A planned sample size 104 patient provide 97 % power 2-tailed α 0.05 detect 4 kg difference weight 12 month follow-up .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Males ≥ 18 year age 2 . Pathologically confirm , adenocarcinoma prostate either hightier intermediate high risk prostate cancer : a. Hightier intermediate risk prostate cancer : i. Gleason score = 7 PSA 10 20 ng/mL b . High risk prostate cancer : i. T3 ; ii . Gleason Score ≥ 8.0 ; iii . PSA ≥ 20 ng/mL . 3 . Normoglycemic Impaired Fasting Glucose45 define : 1 . Fasting Plasma Glucose ≤ 6.9 ; 2 . HbA1c &lt; 6.5 % 4 . Deemed fit undergo curative intent external beam radiation therapy concurrent androgen deprivation therapy attend radiation oncologist . 5 . Accessible followup clinical laboratory assessment . 1 . Patients evidence ( either image pathology ) distant metastatic spread disease . . Patients pelvic lymph node ( i.e . N1 disease ) NOT consider distant metastasis include trial , meeting study criterion . 2 . PSA ≥ 100 ng/mL 3 . Patients meet ≥1 Canadian Diabetes Association criteria45 diagnosis diabetes : 1 . Fasting Plasma Glucose ≥ 7.0 mmol/L ; 2 . HbA1C ≥ 6.5 % ; 3 . Plasma Glucose level ≥ 11.1 mmol/L 2 hour follow 75g oral glucose load , know , within past 28 day ; 4 . Random Plasma Glucose level ≥ 11.1 mmol/L , know , within past 28 day 4 . Patient currently take metformin take metformin within past 12 month . 5 . History lactic acidosis condition predispose lactic acidosis including32 : . Impaired Renal Function ( eGFR &lt; 30 ) ; b. Liver disease , include alcoholic liver disease , demonstrate follow parameter : i. AST &gt; 1.8 x upper limit normal ii . ALT &gt; 1.8 x upper limit normal iii . Alkaline Phosphatase &gt; 2x upper limit normal iv . Serum total bilirubin ≥ upper limit normal c. Alcohol abuse ( habitual intake ≥3 alcoholic beverage per day ) sufficient cause hepatic toxicity d. Severe infection 6 . Patients prior bilateral orchiectomy . 7 . Patients prior prostatectomy 8 . Patients unable provide inform consent 9 . Prior history malignancy ( exception adequately treat nonmelanomatous skin cancer solid tumor treat curatively evidence disease ≥ 5 year ) . 10 . Patients hormonal therapy 3 month prior registration trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>metformin</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>weight gain</keyword>
</DOC>